Inovio Pharmaceuticals, Inc.
INO
$2.02
$0.105.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 65.30K | 117.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 65.30K | 117.00K | -- |
| Cost of Revenue | 13.33M | 14.52M | 16.09M | 12.89M | 18.73M |
| Gross Profit | -13.33M | -14.52M | -16.03M | -12.77M | -18.73M |
| SG&A Expenses | 7.88M | 8.56M | 9.03M | 7.60M | 8.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.21M | 23.08M | 25.12M | 20.49M | 27.35M |
| Operating Income | -21.21M | -23.08M | -25.05M | -20.37M | -27.35M |
| Income Before Tax | -45.50M | -23.52M | -19.69M | -19.38M | -25.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.50M | -23.52M | -19.69M | -19.38M | -25.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.50M | -23.52M | -19.69M | -19.38M | -25.17M |
| EBIT | -21.21M | -23.08M | -25.05M | -20.37M | -27.35M |
| EBITDA | -20.86M | -22.73M | -24.68M | -19.95M | -26.93M |
| EPS Basic | -0.87 | -0.61 | -0.51 | -0.65 | -0.89 |
| Normalized Basic EPS | -0.55 | -0.38 | -0.32 | -0.40 | -0.58 |
| EPS Diluted | -0.87 | -0.61 | -0.51 | -0.65 | -0.89 |
| Normalized Diluted EPS | -0.55 | -0.38 | -0.32 | -0.40 | -0.58 |
| Average Basic Shares Outstanding | 52.17M | 38.83M | 38.61M | 29.99M | 28.14M |
| Average Diluted Shares Outstanding | 52.17M | 38.83M | 38.61M | 29.99M | 28.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |